Bioperfectus Jointly Cooperate with FIND to Accelerate the COVID-19 Self-testing Capacity in LMICs

Company news
2022-02-24

 

  • Bioperfectus, one of the leading in-vitro diagnostics providers for infectious diseases, has partnered with FIND, the global alliance for diagnostics, to lift the COVID-19 self-testing capacity in low- and middle-income countries (LMICs).
  • Based on the requirements provided by FIND in LMICs, the bioPerfectus COVID-19 Ag Self-test Kit is designed to be easy to use, accurate, and affordable.
  • In the support package, FIND will conduct independent clinical evaluations of the performance of the self-tests.
  • Bioperfectus has committed to manufacturing COVID-19 self-tests and making them available to LMICs.

 

Shanghai, China--Feb 24, 2022. Bioperfectus, one of the leading in-vitro diagnostics providers for infectious diseases, has partnered with FIND, the global alliance for diagnostics, to accelerate the availability of affordable SARS-CoV-2 self-tests in low- and middle-income countries (LMICs).

 

Upon the request for proposals (RFP) process launched by FIND in March 2021, in the context of the Access to COVID-19 Tools (ACT) Accelerator diagnostics pillar, which includes strengthening capacity for countries to expand access to COVID-19 testing based on strategies to reach people where they live, work, and seek care, such as community-based testing and self-testing. In response to the open call, Bioperfectus R&D and International Sales & Marketing Division teams joined the communication and collaboration, with fast reaction to the COVID-19 pandemic, advanced R&D capacity, affordability and unique design of “ONE-STEP” COVID-19 Self-testing product, Bioperfectus was chosen among over 80 applicants in fulfilling the criteria including the technical performance of the test, suitability for self-administration, and affordability for LMICs.

 

The investment is funded by the German Federal Ministry of Education and Research (BMBF) through KfW and other donors through grants to FIND. FIND will supplement this financial investment with technical support and conduct an independent evaluation of the performance and usability of the tests in the settings of intended use. All help is dependent on a series of mutually agreed project milestones being successfully met.

 

We Bioperfectus are very honoured to cooperate with FIND to offer bioPerfectus COVID-19 Ag Self-test Kit to LMICs and bridge the gap between the LMICs and HICs(High-income countries) in COVID-19 Self-testing.

 

About Bioperfectus

 

Bioperfectus, a public listed company at Shanghai Stock Exchange (SSE:688399), has been one of the leading molecular diagnostic solution providers specialised in infectious diseases ever since 2010. With headquarter located in Jiangsu, subsidiaries in Shanghai, Beijing, Xi'an, Taizhou, Hainan and Yinchuan. Bioperfectus is pioneering in the molecular diagnostics market with our products ranging from real-time PCR kits, nucleic acid extraction systems, rapid tests and automation laboratory devices. Young and passionate, Bioperfectus people are working steadily and firmly to achieve our dream to create a healthier future for our next generations. For more information, please visit www.bioperfectus.com.

 

About FIND

 

FIND, the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnosis worldwide. We connect countries and communities, funders, decision-makers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems. We are working to save 1 million lives through accessible, quality diagnosis and save US$1 billion in healthcare costs to patients and health systems. We are co-convener of the Access to COVID-19 Tools (ACT) Accelerator diagnostics pillar and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation. For more information, please visit www.finddx.org.

 

About the ACT-Accelerator

 

The Access to COVID-19 Tools (ACT) Accelerator is a global coalition of organisations developing and deploying the new diagnostics, treatments and vaccines needed to end the acute phase of the pandemic. Pooling the expertise of its many partners, the ACT-Accelerator has quickly ushered in rapid, affordable tests and effective medicines for low and middle-income countries and established the COVAX facility for the equitable procurement and distribution of vaccines in low- and lower-middle-income countries. The ACT Accelerator partnership was formed at the pandemic in response to a call from G20 leaders and was launched by WHO, the European Commission, France, and the Bill & Melinda Gates Foundation.

 

The URL of the press release on FIND website, please click here>>

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14